CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer

Debbie O'reilly, Tim Downing, Sana Kouba, Marie Potier-cartereau, Declan J. Mckenna, Christophe Vandier, Paul J. Buchanan

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
69 Downloads (Pure)


Androgen deprivation therapy (ADT) is the main treatment for advanced prostate cancer (PCa) but resistance results in progression to terminal castrate resistant PCa (CRPC), where there is an unmet therapeutic need. Aberrant intracellular calcium (Cai2+) is known to promote neoplastic transformation and treatment resistance. There is growing evidence that voltage gated calcium channel (VGCC) expression is increased in cancer, particularly CACNA1D/CaV1.3 in CRPC. The aim of this study was to investigate if increased CaV1.3 drives resistance to ADT and determine its associated impact on Cai2+ and cancer biology. Bioinformatic analysis revealed that CACNA1D gene expression is increased in ADT treated PCa patients. This was corroborated in both in vivo LNCaP xenograft mouse and in vitro PCa cell line models, which demonstrated a significant increase in CaV1.3 protein expression following ADT with bicalutamide. Expression was found to be of a shortened 170kDa CaV1.3 isoform associated with plasma and intracellular membranes, which failed to induce calcium influx following membrane depolarisation. Instead, under ADT CaV1.3 mediated a rise in basal cytosolic calcium and an increase in store operated calcium entry (SOCE). This mechanism was found to promote the proliferation and survival of ADT resistant CRPC cells. Overall, this study demonstrates for the first time in PCa that under ADT specific CaV1.3 isoforms promote an upregulation of SOCE which contributes to treatment resistance and CRPC biology. Thus, this novel oncochannel represents a target for therapeutic development to improve PCa patient outcomes.
Original languageEnglish
Article number102554
Pages (from-to)1-11
Number of pages11
JournalCell Calcium
Early online date12 Feb 2022
Publication statusPublished (in print/issue) - 1 May 2022

Bibliographical note

Funding Information:
This project was supported by Dublin City University School of Nursing, Psychotherapy and Community Health PhD studentship [2016- 18 ]; Irish Research Council (IRC) Government of Ireland Postgraduate Scholarship [ GOIPG/2018/373 , 2018-21]; and an Ulysses Award [2018] part funded by the IRC and ministères de l'Europe et des affaires étrangères et de l'enseignement supérieur, de la recherche et de l'innovation.

Publisher Copyright:
© 2022 The Author(s)


  • Prostate Cancer
  • Androgen Deprivation Therapy
  • CaV1.3
  • Store operated calcium entry
  • Aberrant Intracellular Calcium


Dive into the research topics of 'CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer'. Together they form a unique fingerprint.

Cite this